Moreover, evaluation of the CCL3 and CCL4 levels may be helpful for selecting DLBCL patients likely to benefit from doxorubicin treatment in combination with the velcade or ibrutinib. The gene discussed is CCL3; the disease is diffuse large B-cell lymphoma.